China Metastatic Liver Cancer Clinical Registry Cohort Database

This study is led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close collaboration with multiple participating centers nationwide. The primary objective is to establish a standardized, large-scale clinical cohort database specifically for metastatic liver cancer. By collecting comprehensive data on patient demographics, primary tumor characteristics, systemic therapies, and local interventions, this registry aims to elucidate the clinical patterns and prognostic factors of secondary liver malignancies. This database will serve as a robust platform for conducting high-quality real-world studies and advancing evidence-based clinical research in the management of metastatic liver cancer.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Liver Metastases Colonic Diseases Colorectal Cancer Metastatic Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms Liver Cancer Liver Diseases Liver Neoplasms Metastases to Liver Neoplasms Neoplasms by Site Rectal Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with histologically or radiologically confirmed metastatic liver cancer.
Age ≥ 18 years.
Patients who have voluntarily signed the informed consent form.
Patients with complete baseline clinical data.

Exclusion criteria

Patients with primary liver cancer (e.g., hepatocellular carcinoma).
Patients with other malignant tumors that may interfere with the evaluation of liver metastasis.
Patients who have previously participated in other interventional clinical trials.
Patients with severe cognitive disorders or communication barriers that prevent informed consent.
Patients with incomplete or missing key clinical data.

Treatment and study plan

Standard of Care for Metastatic Liver Cancer

Procedure

In this observational patient registry, no specific interventional procedure is assigned by the investigators. Patients included in the database receive standard clinical management and treatments for metastatic liver cancer according to current clinical guidelines and physician's discretion. These procedures may include hepatectomy, ablation, transarterial chemoembolization (TACE), systemic chemotherapy, targeted therapy, or immunotherapy. This registry aims to evaluate the real-world effectiveness and safety of these standard interventions.

Primary outcomes

Overall Survival

Time frame: Up to 10 years

The time interval from the date of initial diagnosis (or date of enrollment/surgery) to the date of death from any cause.

Secondary outcomes

Progression-Free Survival

Time frame: Up to 10 years

Description: The time interval from the date of enrollment (or initial treatment) to the date of the first documented disease progression (local recurrence or distant metastasis) or death from any cause, whichever occurs first.
Treatment-Related Adverse Events

Time frame: Within 90 days post-treatment

The incidence and severity of postoperative complications or treatment-related adverse events, graded according to the Clavien-Dindo classification (for surgical complications) or CTCAE (Common Terminology Criteria for Adverse Events) version 5.0.

Study contacts

Contact information is provided by the study sponsor or research team.

Jizhou Wang, MD PhD

CONTACT

[email protected]

+86 13836135864

Lianxin Liu, MD PhD

CONTACT

[email protected]

+86 13845159888

Sponsors and collaborators

Lead sponsor

Anhui Provincial Hospital

Other Gov

Registry information

Important dates

Study start: 2026
Primary completion: 2031
Study completion: 2036
First posted: May 22, 2026
Registry last updated: May 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting